ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Does early ECLS improve survival in patients with AMI and cardiogenic shock? In this interview, Holger Thiele MD and Sidney C. Smith Jr. MD, MACC, discuss ESC Hot Line: ECLS-SHOCK - venoarterial membrane oxygenation in cardiogenic shock.  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Colchicine did not significantly reduce the incidence of two common cardiovascular complications: Perioperative AF and myocardial injury after non-cardiac surgery (MINS).  However, there was an encouraging signal of benefit for colchicine to reduce the incidence of adverse cardiovascular outcomes in patients undergoing major noncardiac thoracic surgery, which requires further study.   In this interview, David Conen MD, MPH, and Joseph E. Marine MD, MBA, FACC discuss ESC Hot Line: COP-AF - Colchicine for the prevention of perioperative atrial fibrillation after major thoracic surgery.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Contrary to findings from observational studies which are inherently affected by bias, digoxin use in randomised controlled trials (RCTs) did not lead to excess mortality in our meta-analysis of 87 studies. There is evidence that digoxin can reduce heart failure-related deaths and hospitalizations. This has implications in treating concomitant atrial fibrillation and heart failure, with two RCTs currently underway to improve our evidence base.    In this interview, Asgher Champsi MD, and Alison L. Bailey MD, FACC discuss ESC Late-Breaker: DIG-META: Digoxin in heart failure and atrial fibrillation.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

The rates of stroke after left atrial appendage occlusion with the Watchman device in real-world clinical practice in the US is relatively low and consistent with those from clinical trials despite the high thromboembolic risk of the patients undergoing the procedure. The rates of death are relatively high in this elderly population with high rates of comorbidities, highlighting the need for shared decision-making regarding the procedure.   In this interview, James V. Freeman MD, MPH, MS, and Joseph E. Marine MD, MBA, FACC, with Purvi Parwani MBBS, MPH, FACC, discuss Long-term Outcomes Following Left Atrial Appendage Occlusion with a Watchman Device: Outcomes from the National Cardiovascular Data Registry.  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Currently no approved therapies exist to target obesity-related heart failure with preserved ejection fraction, a condition increasing in prevalence and associated with high symptom burden. In this interview, Mikhail Kosiborod MD, and Alison L. Bailey MD, FACC, discuss ESC Hot Line: STEP HFpEF: once-weekly semaglutide in people with HFpEF and obesity.    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Results presented at the European Society of Cardiology Congress 2023 further support the long-term use of bempedoic acid in patients at high-risk of cardiovascular events and demonstrate particular benefit in those with diabetes. In this interview, Stephen J. Nicholls MBBS, PhD, FACC and Erin D. Michos, MD, MHS, FACC, discuss the total events analysis from the CLEAR Outcomes trial.   This ACCEL episode is part of an ACC course titled Bempedoic Acid: New Evidence Transforming the LDL-C Treatment Landscape. Educational grant support is provided by Esperion. More content will be available here soon.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

What is known about the use of wearables and their impact on health outcomes and healthcare use among patients with atrial fibrillation.    In this interview, Dipak Kotecha MBChB, PhD and Sidney C. Smith Jr. MD, MACC, discuss “ESC Late-Breaker: RATE-AF trial wearables study.”   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL